This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
May 9-12, 2022 | In-Person + DigitalHynes Convention Center, Boston

Samuele Cazzamalli, Ph.D.
Head of Small Molecule Therapeutics at Philochem Ag


Samuele Cazzamalli studied Medicinal Chemistry at the University of Milan. During his doctoral studies at ETH Zürich in the group of Prof. Dario Neri (2015-2018), Samuele has generated novel Antibody-Drug Conjugate, Small Molecule-Drug Conjugate and Small Molecule-Radio Conjugate products for applications in oncology.

Samuele heads now the Small Molecule Therapeutics R&D unit at Philochem AG (Switzerland), focusing on the development of products based on small organic ligands for tumor-targeting applications.

Agenda Sessions

  • Pan-tumoral Small Molecule-Drug Conjugates targeting Fibroblast Activation Protein in Solid Lesions